Eric J. Sherman, MD, examines the phase 3 COSMIC-311 trial with cabozantinib in radioiodine-refractory differentiated thyroid cancer.
Eric J. Sherman, MD, highlights trends he observed with immunotherapy in the head and neck cancer space.
Eric J. Sherman, MD, of Memorial Sloan Kettering Cancer Center highlights research on adjuvant capecitabine in nasopharynx cancer.
Results of the phase 3 JUPITER-02 trial presented at ASCO 2021 support the use of toripalimab plus chemotherapy for recurrent or metastatic nasopharyngeal carcinoma.